Gastric Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Gastric Cancer is a $5.6B market at peak maturity with limited primary-indication dominance and significant secondary-indication contamination in the dataset.
Key Trends
- Single primary-indication product (CYRAMZA) represents minimal market share; most top products treat gastric cancer secondarily
- Heavy concentration in tyrosine kinase inhibitors and multi-target inhibitors reflecting precision oncology shift
- Substantial trial pipeline (539 studies) suggests emerging combination and biomarker-driven strategies
Career Verdict
Gastric cancer specialization offers niche expertise and strong hiring volume, but be aware that many marketed products in this space are portfolio treatments rather than focused gastric cancer programs.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | CYRAMZA (ramucirumab) | Eli Lilly and Company | $4M | 0.07% | Peak | Stable |
Drug Class Breakdown
niche, established
growing adoption in combos
established second-line
growing in HRD+ subset
Career Outlook
StableGastric cancer is a mature, stable indication with established treatment paradigms and limited breakthrough innovation headroom. The market is dominated by multi-indication products rather than gastric-focused therapies, which means career trajectories often involve portfolio management across oncology rather than deep specialization. However, the large patient population globally and high unmet need in certain geographies (Asia-Pacific) provide ongoing justification for R&D and commercial investment.
Breaking In
Entry-level professionals should focus on commercial roles (highest job volume) or clinical operations (highest pay) with a willingness to manage gastric cancer as part of a broader oncology portfolio rather than a standalone specialization.
For Experienced Professionals
Experienced professionals should leverage Asia-Pacific geography expertise and biomarker knowledge to differentiate; consider strategic roles managing combination studies or real-world evidence initiatives where gastric cancer is gaining momentum in precision oncology.
In-Demand Skills
Best For
Hiring Landscape
Gastric cancer specialization supports 7,080 jobs across 15 companies, with AstraZeneca (1,373 jobs), Pfizer (542), and Bristol Myers Squibb (720) as primary employers in this space. Commercial roles dominate (1,128 positions) followed by manufacturing (556) and R&D (507), reflecting mature market dynamics. Entry-level and mid-career positions are most available in commercial and clinical operations; senior roles cluster in R&D and medical affairs.
Top Hiring Companies
By Department
Gastric cancer roles are highest-paid in Clinical Operations ($307K avg) and competitive in Commercial ($257K avg); mature market limits explosive growth but offers stability and established career ladders.
On Market (3)
Approved therapies currently available
Competitive Landscape
70 companies ranked by most advanced pipeline stage
+40 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 24,480 patients across 50 trials
Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations
RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2
Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients
A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy
Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy
Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer
A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention
Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)
Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer
A Safety and Efficacy Study in Patients With Gastric Cancer
Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)
A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Study of ONO-4538 in Gastric Cancer
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery
Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer
Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients
A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
Related Jobs in Oncology
Alternance Assistant(e) Engagement Clients Oncologie H/F
Executive Director, Asset Development Team Leader
Manager, Sales Oncology
Practicante Universitario Marketing Oncología
Medical Advisor Oncology
Senior Customer Representative Oncology (m/f/d)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.